Shell Asset Management CO Seagen Inc. Transaction History

Shell Asset Management CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$191.51 - $216.16 $50,367 - $56,850	-263 Reduced 4.65%	5,397 $1.15 Million
Q2 2023 Jul 28, 2023	BUY	$187.64 - $206.25 $555,039 - $610,087	2,958 Added 109.47%	5,660 $1.09 Million
Q4 2022 Feb 07, 2023	SELL	$117.37 - $139.17 $53,403 - $63,322	-455 Reduced 14.41%	2,702 $347,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $31,382 - $41,785	-232 Reduced 6.85%	3,157 $432,000
Q2 2022 Aug 09, 2022	SELL	$108.81 - $179.33 $517,282 - $852,534	-4,754 Reduced 58.38%	3,389 $600,000

Q1 2022 May 04, 2022	BUY	$119.61 - $157.85 $48,920 - $64,560	409 Added 5.29%	8,143 $1.17 Million
Q4 2021 Feb 09, 2022	BUY	$142.57 - $190.86 $875,094 - $1.17 Million	6,138 Added 384.59%	7,734 $1.2 Million
Q3 2021 Nov 04, 2021	SELL	$142.45 - $169.82 $107,122 - $127,704	-752 Reduced 32.03%	1,596 $271,000
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $142,509 - $169,960	1,055 Added 81.59%	2,348 $371,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $125,409 - $174,009	-912 Reduced 41.36%	1,293 $180,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $363,009 - $467,305	2,205 New	2,205 $386,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.